Published in Rev Urol on January 01, 2008
Lower urinary tract symptoms in men. BMJ (2014) 0.95
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol (2009) 0.77
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol (2016) 0.76
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 5.49
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (2002) 4.40
Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med (1994) 4.00
Drug induced QT prolongation and torsades de pointes. Heart (2003) 3.97
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Prescribing amiodarone: an evidence-based review of clinical indications. JAMA (2007) 3.10
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation (1992) 2.43
Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J (2007) 1.99
Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) (2003) 1.78
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther (2005) 1.74
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther (2007) 1.65
Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm (2005) 1.63
Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol (2005) 1.62
Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation (2002) 1.30
Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther (2007) 1.14
Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol (2007) 1.14
QT interval variability on the body surface. J Electrocardiol (1984) 1.04
QT interval measurements. Card Electrophysiol Rev (2002) 0.94
Drug-induced torsade de pointes. Circulation (1999) 0.88
Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace (2007) 0.80
Search for new alpha1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. Indian J Urol (2007) 0.78
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40
Interference in implanted cardiac devices, part II. Pacing Clin Electrophysiol (2002) 3.24
Prescribing amiodarone: an evidence-based review of clinical indications. JAMA (2007) 3.10
Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol (2002) 2.96
Gleason 6 prostate cancer: serious malignancy or toothless lion? Oncology (Williston Park) (2014) 2.06
Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J (2007) 1.99
Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol (2005) 1.98
Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology (2010) 1.78
An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida. J Urol (2005) 1.78
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology (2009) 1.67
Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study. Eur Urol (2013) 1.62
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol (2010) 1.58
Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology (2013) 1.56
Endoscopy in patients with implanted electronic devices. Gastrointest Endosc (2007) 1.55
What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol (2002) 1.54
Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy? BJU Int (2008) 1.53
The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol (2007) 1.50
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med (2005) 1.49
The prognostic value of cardiac SPECT performed at the primary care physician's office. J Nucl Cardiol (2013) 1.45
Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells (2006) 1.43
Left bundle branch block during orthodromic reciprocating tachycardia: where is the accessory pathway? Heart Rhythm (2006) 1.39
"Proud flesh" post permanent pacemaker. Heart Rhythm (2010) 1.39
Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing post-prostatectomy hernia. BJU Int (2012) 1.39
Presence and severity of noncalcified coronary plaque on 64-slice computed tomographic coronary angiography in patients with zero and low coronary artery calcium. Am J Cardiol (2007) 1.38
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA (2003) 1.36
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol (2007) 1.36
Narrative review: Electrocution and life-threatening electrical injuries. Ann Intern Med (2006) 1.30
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol (2004) 1.27
Open Versus Laparoscopic Versus Robot-Assisted Laparoscopic Prostatectomy: The European and US Experience. Rev Urol (2010) 1.25
Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol (2005) 1.19
Influence of body weight and prostate volume on intraoperative, perioperative, and postoperative outcomes after radical retropubic prostatectomy. Urology (2003) 1.18
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol (2007) 1.18
Skin preparation for the prevention of surgical site infection: which agent is best? Rev Urol (2009) 1.14
Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res (2009) 1.13
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol (2003) 1.12
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol (2009) 1.12
The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Cardiovasc Ultrasound (2014) 1.11
Right coronary artery occlusion during RF ablation of typical atrial flutter. J Cardiovasc Electrophysiol (2010) 1.10
Post-prostatectomy incontinence during sexual activity: a single center prevalence study. J Urol (2011) 1.09
The prostatic utricle is not a Müllerian duct remnant: immunohistochemical evidence for a distinct urogenital sinus origin. J Urol (2004) 1.08
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol (2004) 1.08
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol (2009) 1.07
Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology (2005) 1.05
Removal of urinary catheter on postoperative day 3 or 4 after radical retropubic prostatectomy. Urology (2003) 1.02
Spontaneous renal artery dissection. Rev Urol (2007) 1.02
Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol (2008) 0.96
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol (2011) 0.96
Spontaneous retroperitoneal hemorrhage caused by segmental arterial mediolysis. Rev Urol (2006) 0.96
Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol (2011) 0.96
Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy. J Urol (2010) 0.96
Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer. Eur Urol (2013) 0.95
Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol (2002) 0.95
Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int (2009) 0.95
Management of localized prostate cancer and an incidental ureteral duplication with upper pole ectopic ureter inserting into the prostatic urethra. Rev Urol (2008) 0.95
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. J Urol (2003) 0.94
Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem (2011) 0.94
Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol (2012) 0.91
Chemotherapy and cardiotoxicity. Rev Cardiovasc Med (2008) 0.91
Bmp7 functions via a polarity mechanism to promote cloacal septation. PLoS One (2012) 0.91
Women with atrial fibrillation: Greater risk, less attention. Gend Med (2009) 0.91
The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med (2005) 0.91
Factors predisposing to the development of anastomotic strictures in a single-surgeon series of radical retropubic prostatectomies. BJU Int (2006) 0.91
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol (2007) 0.91
Isthmus dependent atrial flutter cycle length correlates with right atrial cross-sectional area. Indian Pacing Electrophysiol J (2009) 0.90
Managing and preventing acute urinary retention. Rev Urol (2005) 0.90
Testosterone in prostate cancer: the Bethesda consensus. BJU Int (2011) 0.90
Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med (2009) 0.89
LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol (2011) 0.88
Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology (2008) 0.88
Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol (2005) 0.88
Open versus laparoscopic radical prostatectomy. Rev Urol (2005) 0.87
Cardiac resynchronization therapy: a potential option for congenitally corrected transposition of the great vessels. J Heart Lung Transplant (2005) 0.86
Gene polymorphisms and prostate cancer: the evidence. BJU Int (2009) 0.86
Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med (2005) 0.85
Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol (2009) 0.85
Evaluating men with benign prostatic hyperplasia. Rev Urol (2004) 0.85
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol (2008) 0.85
Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Urology (2009) 0.85
Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. J Urol (2012) 0.84
Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy (2010) 0.84
Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature. Can J Urol (2010) 0.84
Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. Oncotarget (2014) 0.84
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol (2006) 0.84
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis (2012) 0.84
Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Eur Urol (2011) 0.84
Time to return to work and physical activity following open radical retropubic prostatectomy. J Urol (2006) 0.83
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology (2002) 0.83
Intraoperative frozen section analysis of urethral margin biopsies during radical prostatectomy. Urology (2011) 0.83
Tamsulosin reduces the incidence of acute urinary retention following early removal of the urinary catheter after radical retropubic prostatectomy. Urology (2003) 0.83
Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol (2005) 0.83
Catheter ablation of hemodynamically unstable ventricular tachycardia with mechanical circulatory support. Int J Cardiol (2013) 0.82
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys (2010) 0.82